$OXIS News article out! One such segment, which has garnered more attention from "safe" investors, has been that of biotech. Companies like Insys Therapeutics and GW Pharma are focused more on the prescription uses of the drugs active ingredients as opposed to the more "over-the-counter" style products that launched the crazy in early 2014. In the small cap space, Oxis International through its subsidiary, Oxis Biotech, has been captivating penny stock traders over the last few weeks. Material announcements include the addition of two key members to the company's scientific advisory board. These include the likes of the foremost authority on CBD research, Dr. Sean Xie as well as Dr. James Mule who also sits as a Special Government Employee of the NCI and the FDA. In addition to this, Oxis Biotech, Inc. executed definitive agreements licensing certain assets for the treatment of Multiple Myeloma. These developments have continued to ignite more market activity as OXIS pushes toward higher price levels and realizes increased trading volume. http://finance.yahoo.com/news/cannabis-stocks-winning-portfolio-now-133000957.html